From The Motley Fool · Motley Fool Transcribing · · 2m
Danaher Q3 2026 Earnings Beat
Danaher reports 8.5% revenue growth and 5.5% core growth excluding respiratory revenue in Q3 2026.
In brief
Danaher reports 8.5% revenue growth and 5.5% core growth excluding respiratory revenue in Q3 2026. Danaher's Q3 2026 earnings exceeded expectations with $6.6 billion revenue, 5.5% core growth excluding respiratory revenue, and $2.11 adjusted diluted EPS. Originally reported by The Motley Fool.
Q3 2026 Results
Danaher reported third quarter revenue of $6.6 billion, representing 8.5% growth compared to Q3 2025.
Core Revenue Growth
Core revenue growth excluding respiratory revenue reached 5.5%, accelerating 100 basis points from Q2 2026.
Respiratory Revenue
Respiratory revenue totaled $350 million, down year over year due to lower global infection rates.
Biotechnology Performance
Biotechnology core revenue grew 5% with bioprocessing performance toward the upper end of mid-single digits.
Life Sciences Growth
Life Sciences core revenue grew 4.5% led by SCIEX's pharma demand and ZenoTOF 8600 momentum.
Diagnostics Performance
Diagnostics core revenue excluding respiratory grew 7% with mid-single-digit clinical diagnostics growth.
China Growth
China core revenue grew high single digits across all three operating segments.
Masimo Integration
Masimo, acquired as a Danaher business, delivered high single-digit revenue growth in Q3 2026.
Q4 Guidance
Q4 2026 core growth guidance excludes respiratory revenue at 4% to 5% with 150 basis point headwind.
2027 Growth Target
2027 core revenue growth starting point excludes respiratory revenue at 4% to 5%.
Acquisitions
Leica Biosystems acquired StatLab in early Oct. 2026 to strengthen oncology pathology workflow.
AI Partnership
Danaher announced NVIDIA partnership to advance AI-powered autonomous lab workflows.
Free Cash Flow
Free cash flow reached $1.6 billion for Q3 2026 and $4 billion for first nine months of 2026.
Operating Margin
Adjusted operating profit margin reached 29.0%, improving 110 basis points year over year.
CEO Perspective
CEO Julie Sawyer Montgomery stated, 'unambiguous share gain is our true report card.'
“unambiguous share gain is our true report card”
Strategic Priorities
Danaher prioritizes commercial excellence, innovation, talent, and disciplined capital allocation.
In short
Danaher's Q3 2026 earnings exceeded expectations with $6.6 billion revenue, 5.5% core growth excluding respiratory revenue, and $2.11 adjusted diluted EPS.
